Ontology highlight
ABSTRACT:
SUBMITTER: Downey-Kopyscinski S
PROVIDER: S-EPMC6177641 | biostudies-literature | 2018 Oct
REPOSITORIES: biostudies-literature
Downey-Kopyscinski Sondra S Daily Ellen W EW Gautier Marc M Bhatt Ananta A Florea Bogdan I BI Mitsiades Constantine S CS Richardson Paul G PG Driessen Christoph C Overkleeft Herman S HS Kisselev Alexei F AF
Blood advances 20181001 19
Proteasome inhibitors bortezomib, carfilzomib and ixazomib (approved by the US Food and Drug Administration [FDA]) induce remissions in patients with multiple myeloma (MM), but most patients eventually become resistant. MM and other hematologic malignancies express ubiquitous constitutive proteasomes and lymphoid tissue-specific immunoproteasomes; immunoproteasome expression is increased in resistant patients. Immunoproteasomes contain 3 distinct pairs of active sites, β5i, β1i, and β2i, which a ...[more]